Scribe Therapeutics, Inc.

424B4 priced

Price $15.00 · 8,580,000 shares · Gross proceeds $128,700,000

FWP supplemental

Price $15.00 · 8,580,000 shares · Gross proceeds $128,700,000

Scribe Therapeutics announced the pricing of its upsized initial public offering (IPO) of 8,580,000 shares at $15.00 per share, raising $128.7 million in gross proceeds. The offering includes a 30-day underwriter option to purchase an additional 1,287,000 shares. The company also executed a concurrent $7.5 million private placement with Sanofi. Shares are set to trade on Nasdaq under 'SCTX' with closing expected July 27, 2026. Underwriters include Leerink Partners, Goldman Sachs, Guggenheim, and Wells Fargo.

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Range $13.00 to $15.00 · 7,150,000 shares

Scribe Therapeutics, Inc. reported significant declines in collaboration revenue for Q1 2026 compared to Q1 2025, driven by the expiration of milestone-based payments from Lilly and completion of Sanofi workplans. Research and development expenses decreased by 29% ($16.0M to $11.3M) due to reduced headcount, preclinical program completions, and lower manufacturing activities. General and administrative expenses dropped 50% ($6.7M to $3.4M) primarily from deferred offering cost releases. The company recorded a net loss of $17.3M in Q1 2026, compared to $3.4M in Q1 2025, with a significant increase in net loss attributed to a $4.6M unrealized loss on convertible note fair value adjustments.

S-1/A amended

Scribe Therapeutics, Inc. reported a significant decline in collaboration revenue, dropping to $2.2 million in Q1 2026 from $17.1 million in Q1 2025, primarily due to milestone achievements and expired substitution rights with Lilly, along with completed Sanofi workplans. Research and development expenses decreased by 29% to $11.3 million, driven by reduced headcount, completed preclinical programs, and lower manufacturing activities. General and administrative expenses fell 50% to $3.4 million, partially offset by increased personnel costs. The company faces risks related to regulatory approvals, reliance on collaboration revenue, and volatile R&D expenses as it advances its pipeline. A convertible note's fair value fluctuation also impacted financial results.

S-1 filed

Scribe Therapeutics, Inc. reported significant declines in collaboration revenue, particularly from key partners Lilly and Sanofi, with Q1 2026 revenue down 87% year-over-year. Research and development expenses decreased by 29% to $11.3 million, driven by reduced headcount and project handovers, while general and administrative costs fell 50% to $3.4 million. The company recorded a net loss of $17.3 million in Q1 2026, compared to $3.4 million in Q1 2025, with losses exacerbated by a $4.6 million unrealized loss on its convertible note. Operating losses widened significantly, and the company remains dependent on collaboration milestones for revenue, with no product candidates yet approved for commercialization.

DRS/A amended

DRS/A amended

DRS filed